Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo patch Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

NCT01096966
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Bupivacaine TTS (Bupivacaine Patch), Placebo patch
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 70 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Tempe, Arizona • La Mesa, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 19, 2026, 7:58 AM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

NCT02365870
View directory record Official record
Conditions
Anxiety Disorders, Parkinson Disease
Interventions
rotigotine transdermal patch, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use

NCT04084210
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Juul Electronic cigarette, Very Low Nicotine Cigarettes, Active Nicotine Patch, Placebo Patch
Device · Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UW Quitting Using Intensive Treatment Study (QUITS)

NCT03176784
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Nicotine patch, Placebo Patch, Placebo Pill
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
56
States / cities
Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 19, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional Results available

Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis

NCT02466074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 19, 2026, 7:58 AM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KEEPS Mammographic Density And Breast Health Ancillary Study

NCT02524561
View directory record Official record
Conditions
Mammographic Density, Abnormal Mammogram
Interventions
CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 3 Interventional Results available

Erlotinib Prevention of Oral Cancer (EPOC)

NCT00402779
View directory record Official record
Conditions
Oral Cancer
Interventions
Erlotinib, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 4 Interventional

Prevention and Treatment of Common Hyperglycemia in Surgery Pilot

NCT06624956
View directory record Official record
Conditions
Surgery, Non Diabetic Hyperglycemia
Interventions
glucose, insulin, and potassium (GIK), Crystalloid Infusion
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 19, 2026, 7:58 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

NCT03728933
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 19, 2026, 7:58 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)

NCT00775749
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
transdermal nicotine patch, placebo patch
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 19, 2026, 7:58 AM EDT
Suspended Phase 1 Interventional

Safety of MOON101 for the Treatment of Peanut Allergy

NCT07580898
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dose A, Dose B, Dose C, Dose D, Dose E, Placebo
Combination Product
Lead sponsor
Moonlight Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 7:58 AM EDT
Not listed Phase 2 Interventional

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

NCT02544204
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
JVS-100, Placebo
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 7:58 AM EDT
Terminated Phase 4 Interventional Results available

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

NCT03051516
View directory record Official record
Conditions
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
27 Years to 69 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

NCT02906644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
lorcaserin, nicotine patch, placebo lorcaserin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 19, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms Underlying Nicotine and Alcohol Combinations

NCT02049268
View directory record Official record
Conditions
Focus: Effects of Nicotine and Alcohol on Brain Circuits
Interventions
Nicotine + Alcohol, Placebo Nicotine + Alcohol, Nicotine + Placebo Alcohol
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 19, 2026, 7:58 AM EDT